Mary‐Frances McMullin

A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients

Alan K. Burnett, Nigel H. Russell, Robert K. Hills et al. · Blood · 2015 · 295 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +5

Attempts to Optimize Induction and Consolidation Treatment in Acute Myeloid Leukemia: Results of the MRC AML12 Trial

Alan K. Burnett, Robert K. Hills, Donald Milligan et al. · Journal of Clinical Oncology · 2009 · 229 citations · Full text

Medicine, Oncology, Pharmacology +15

European Development of Clofarabine as Treatment for Older Patients With Acute Myeloid Leukemia Considered Unsuitable for Intensive Chemotherapy

Alan K. Burnett, Nigel H. Russell, Jonathan Kell et al. · Journal of Clinical Oncology · 2010 · 149 citations · Full text

Medicine, Oncology, Pharmacology +13

The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial

Alan K. Burnett, Donald Milligan, Anthony P. Goldstone et al. · British Journal of Haematology · 2009 · 140 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia

Mike Dennis, Nigel H. Russell, Robert K. Hills et al. · Blood · 2015 · 49 citations · Full text

Medicine, Hematology, Oncology +16